MedTrace Logo

Nasal Oxygen Therapy After Cardiac Surgery

NCT05308719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1280

Last updated 2025-05-29

No results posted yet for this study

Summary

NOTACS aims to determine if prophylactic use of high-flow nasal therapy (for a minimum of 16 hours after tracheal extubation, inclusive of up to one hour off randomised therapy for transfers around the hospital and/or physio mobilisation) increases days at home in the first 90 days after surgery, for adult patients undergoing cardiac surgery who are at high risk of postoperative pulmonary complications. The study also incorporates a health economic analysis to estimate the incremental cost-effectiveness and cost-utility of HFNT versus standard oxygen therapy at 90 days, from the view-point of the public sector, NHS and patients.

Conditions

Interventions

DEVICE

High Flow Nasal Therapy

High Flow Nasal Oxygen (Airvo2 Device)

Sponsors & Collaborators

  • University Hospitals, Leicester

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • Papworth Hospital NHS Foundation Trust

    lead OTHER_GOV

Principal Investigators

  • Andrew Klein · Royal Papworth Hospital NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2024-12-06
Completion
2024-12-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05308719 on ClinicalTrials.gov